CLIA Waiver for QuickVue® RSV Test
go back to news archives| Quidel Corporation has announced that the U.S. Food and Drug Administration (FDA) granted CLIA waiver for the QuickVue® RSV test for the qualitative detection of respiratory syncytial virus (RSV). The waiver makes the QuickVue RSV test more widely available for use, especially in physician offices and clinics where waived tests are used most frequently. The QuickVue RSV test is simple and accurate, with high sensitivity and specificity. Respiratory syncytial virus is recognized by the American Academy of Pediatrics as the leading cause of pneumonia and bronchiolitis among children two years of age and younger. RSV is a common virus with symptoms that often resemble the common cold. The QuickVue RSV test is intended for use as an aid in the diagnosis of acute RSV viral infections for symptomatic pediatric patients. |
NOTE: This item is from our 'historic' database and
may contain information which is not up to date.
Source : Quidel Corporation View Company Information
Posted on March 7, 2008
advertisement
advertisement
advertisement
advertisement
LATEST MICROBIOLOGY NEWS
MICROBIOLOGY EVENTS
-
10th Annual Microbiome Movement Summit
-
Endotoxin Testing with Sustainable rFC: New Pharmacopoeia Developments and Implementation
-
Introduction to Statistics for Microbiologists
-
Classic and Modern: Integration of Culture Methods and qPCR for Listeria monocytogenes Control
-
Microbial Management in Fuel Storage: Advanced Testing and Biocide Strategies
-
Getting Equipped for the Future with the New MAS-100 Sirius® Microbial Air Sampler
-
AI for Food Safety Professionals
-
Unmasking Endotoxins: A Sample Preparation Strategy to Overcome LER
-
IAFP 2025
-
ADLM 2025
